TRIM24 and CDKN2A Deletion Drive Glioma via Metabolic Reprogramming
New research identifies how TRIM24 and CDKN2A deletion drive glioma by reprogramming mevalonate metabolism, offering a potential dual-targeting therapeutic strategy.
New research identifies how TRIM24 and CDKN2A deletion drive glioma by reprogramming mevalonate metabolism, offering a potential dual-targeting therapeutic strategy.
A molecular study reveals that restricting dietary methionine triggers site-specific acetylation and proteasomal degradation of the epigenetic regulator LSD1 in ...
A prospective study of 61 patients found that apparent diffusion coefficient values correlate with glioma grade and meningioma cellularity, though ...
Researchers discover that the enzyme DPP9 promotes temozolomide resistance in glioma by controlling RFWD3 nuclear localization and sustaining RPA1 stability.
A pharmacokinetic modeling study shows that blood-brain barrier permeability, rather than target binding rate, is the primary driver of dynamic ...
Neurosurgeons report that a transcortical trans-inferior parietal lobule approach provides direct access to posterior thalamic and pulvinar gliomas while sparing ...
A study in Cell & Bioscience identifies AK2 as a key metabolic and immune-related factor in gliomas, with Venetoclax showing ...
A new review maps how the three secreted FGFBP proteins tune FGF signaling in physiology and act as divergent prognostic ...
A newly published protocol outlines how a systematic review will assess Raman spectroscopy as a real-time, label-free diagnostic tool for ...
The 25th International Cancer Imaging Society Meeting proceedings describe MRI biomarkers, structured reporting systems, and quantitative imaging tools that predict ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine